Tiburio Therapeutics
Tiburio Therapeutics is a drug development company that develops novel small molecule treatments for potentially life-threatening rare neuroendocrine tumours and endocrine diseases such as non-functioning pituitary adenoma (NFPA).
Tiburio Therapeutics' lead compound, TBR-760, inhibits cell proliferation and thereby shrinks or halts the growth of tumours without the risks associated with more invasive treatments like transsphenoidal surgery (TSS) or radiation.
